Myeloperoxidase
Myeloperoxidase (MPO) is an inflammation-associated heme enzyme involved in oxidative processes.
Myeloperoxidase (MPO) is an inflammation-associated heme enzyme involved in oxidative processes. It is particularly relevant to neutrophil biology and has been linked to cardiovascular oxidative stress, inflammatory mechanisms, and cancer progression. Because MPO activity can be measured in biological samples, the enzyme is studied both as a mechanistic mediator and as a potential biomarker of inflammatory activity.
MPO is also being investigated as a pharmacological target. Recent work has examined selective MPO inhibition, including the clinical-development candidate mitiperstat, as well as activity-based analytical methods for detecting MPO in complex samples. Its disease relevance has been explored alongside reactive oxygen species, oxidative stress, proinflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-17A (IL-17A), and tumor necrosis factor-α (TNF-α), and inflammatory mediators including matrix metallopeptidase 8 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).
- ANCA testing strategies: A single centre experience over the past decade in a large teaching hospital in the Netherlands. PMID 42715168
Where the papers sit
10 papers study myeloperoxidase directly. The themes below are drawn from those 10. 1 new direction follows.
-
MPO-Related Therapeutics and Disease : Inhibitor discovery, vascular disease, periodontitis, engineered progenitors and catalytic cancer therapy converge only on MPO-related biology. The cluster has no shared disease question or clear direction, spanning therapeutic design, inflammation and cell engineering. 5 papers · 50%
-
MPO Detection and Pharmacology : MPO activity is being measured with sensitive amplification platforms alongside pharmacokinetic characterization of mitiperstat and synovial-fluid assessment after regenerative injections. The shared focus is translating MPO quantification into clinical monitoring, without a single therapeutic direction. 3 papers · 30%
-
ANCA-Associated Vasculitis : Diagnostic work focuses on ANCA testing strategies and early recognition of ANCA-associated glomerulonephritis, including cases with IgA deposition. Antibody specificity, concentration and immunoglobulin findings recur as tools for distinguishing autoimmune vasculitis from other inflammatory disease. 2 papers · 20%
Myeloperoxidase is a regulator of granulocyte-monocyte progenitor proliferation, not merely an inflammatory enzyme, biomarker, or therapeutic target
In the granulocyte-monocyte progenitor expansion and CAR-immunotherapy model, the study found that myeloperoxidase regulates GMP proliferation and can be manipulated to establish a renewable, engineerable source of therapeutic myeloid cells; this assigns MPO a direct hematopoietic progenitor-control role outside the inflammatory, diagnostic, and inhibitor-focused uses represented elsewhere in the set 42320470Jun.
Recent Findings on Myeloperoxidase
MPO-Related Therapeutics and Disease: Elevated MPO tracked intracranial plaque, stenosis, atherosclerotic burden, and plaque progression over approximately 4.7 years 42622237Aug. Periodontitis also showed higher serum MPO alongside cytokines and tissue-remodeling proteins, including Interleukin-6 (IL-6), Interleukin 17A (IL-17A), and Tumor necrosis factor-α (TNF-α), even in systemically healthy participants 41910651Mar. Therapeutic studies pursue distinct MPO-related strategies, including pharmacophore-guided inhibitor discovery, MPO-regulated granulocyte-monocyte progenitor expansion, and peroxidase-like nanozyme catalysis that enhances doxorubicin cytotoxicity through reactive oxygen species 42572067Aug42320470Jun42208681May. These approaches are moving toward MPO-targeted vascular and inflammatory interventions, engineered cellular immunotherapy, and catalytic cancer treatment.
MPO Detection and Pharmacology: MPO activity assays are becoming more sensitive while retaining clinical monitoring applications. A DNA nanowire-assisted CRISPR/Cas12a platform detected MPO activity at 10.20 pg/mL and separated preliminary serum signal distributions between acute coronary syndrome patients and healthy individuals, although eosinophil peroxidase/HOBr-mediated activation remained possible 42503780Jul. Hypertonic dextrose and concentrated growth factor injections both reduced synovial-fluid MPO while improving pain and assisted maximum mouth opening, with no significant difference between treatments 42472796Jul. Mitiperstat pharmacokinetics followed a two-compartment model, and severe renal impairment and lower body weight produced the greatest exposure increases, supporting dose optimization across development programs 42101107May.
ANCA-Associated Vasculitis: ANCA testing in secondary care favored ELISA as the initial method because it provided higher positive predictive value and specificity, while a second test improved specificity when clinical suspicion or antibody concentrations created uncertainty 42715168Sep. The Dutch cohort also found that most ANCA-positive patients did not have ANCA-associated vasculitis, and ANCA concentrations showed wide ranges despite higher values in affected patients 42715168Sep. In a child with renal-limited ANCA-associated glomerulonephritis, school urinary screening detected hematuria and progressive proteinuria before renal dysfunction, while elevated MPO-ANCA accompanied IgA, immunoglobulin M, and C3 deposition 42371244Jun. MPO-ANCA levels and proteinuria normalized after methylprednisolone pulse therapy, rituximab, and azathioprine, reinforcing early urine screening and pathology-guided immunosuppression in pediatric disease.
Written from 10 PubMed abstracts, each one cited by PMID above. Published: 2026-09-02. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.